In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with type 2 diabetes (T2DM). 2. All three agents were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback